The protooncogene c-myc is involved in the regulation of cell growth. Although increased c-Myc expression is found in hypertrophied hearts, the role of c-Myc in the development of cardiac hypertrophy (CH) has never been determined. The aim of this study was to test the effect of heart-specific inhibition of c-Myc expression on the development of coldinduced cardiac hypertrophy (CICH). We hypothesized that heart-specific inhibition of c-Myc expression attenuates CICH. We constructed c-Myc antisense (c-MycAS) plasmid and green fluorescent protein (GFP) plasmid driven by a heartspecific promoter, a-myosin heavy chain (MHC). The cell culture study indicated that c-MycAS can effectively inhibit c-Myc expression and that GFP can express in the rat heart cells. Four groups of rats were used to test the effect of in vivo inhibition of cardiac c-Myc expression on the development of CICH. Three groups received an intravenous injection of c-MycAS, GFP and buffer, respectively, at the beginning of exposure to moderate cold (6.71C), while the last group received buffer and was kept at room temperature (251C) to serve as a control. Blood pressure (BP) of the cold-exposed groups receiving buffer or GFP increased significantly, whereas BP of the c-MycAS group did not increase until 28 days after exposure to cold. Thus, c-MycAS delayed and attenuated cold-induced hypertension (CIH). The antihypertensive effect of c-MycAS was probably due to the decreased cardiac output. Magnetic resonance imaging (MRI) showed that the in vivo left ventricle wall thickness of cold-exposed rats was decreased significantly by c-MycAS. Consistently, the cold-induced increase in heart weight was attenuated by inhibition of cardiac c-Myc expression. The heart specificity of a-MHC promoter was confirmed by the selective inhibition of c-Myc expression in the heart and by the selective expression of both GFP mRNA and GFP protein in the heart. Heartspecific inhibition of c-Myc expression attenuated the development of CICH. The increased c-Myc expression may play a critical role in the pathogenesis of CICH. Thus, heart-specific inhibition of c-Myc expression may be a new and effective approach for the control of CH.
Introduction
The protooncogene c-myc is involved in the regulation of cell proliferation and growth and its role in tumorigenesis has been studied extensively. 1, 2 Interestingly, c-Myc protein (c-Myc) expression is upregulated in cardiomyocytes in responses to a variety of hypertrophic stimuli. [3] [4] [5] [6] [7] [8] [9] In addition to mechanical stimuli, many biochemical factors can induce cardiac hypertrophy (CH). [3] [4] [5] 10, 11 For example, norepinephrine, angiotensin II or thyroid hormones can induce CH in the absence of pressure overload. [3] [4] [5] 11 It is interesting to note that the hormoneinduced CH is accompanied by upregulation of c-myc expression. [3] [4] [5] 10, 11 It was reported that the increased c-myc expression may be associated with cardiac myocyte hypertrophy. 7, [12] [13] [14] [15] [16] [17] Overexpression of c-Myc in cultures of rat cardiac myocytes resulted in an increase in myocyte size and DNA and protein synthesis. 10 By using a transgenic model, Xiao et al. 7 found that activation of c-Myc in adult myocardium is sufficient to induce an increase in myocyte size and protein synthesis and cardiac-specific gene expression seen in CH. Thus, c-Myc may serve as an intracellular transducer of hypertrophic signals in post-mitotic myocardium. Indeed, the increased cardiac c-myc expression was found in patients with CH 13, 14 and in several animal models of CH. 8, 15, 16 However, the cause-effect relationship between the increased c-Myc expression and CH is not clear and may vary with forms of CH. The aim of this study was to determine if the increased cardiac c-Myc expression mediates cold-induced cardiac hypertrophy (CICH) by testing the effect of heart-specific inhibition of c-Myc expression on the development of CICH.
The study of CICH has strong implications for humans because cold temperatures have adverse effects on the human cardiovascular system. [18] [19] [20] [21] [22] [23] [24] [25] [26] People who live in cold regions have increased prevalence in cardiovascular disease. 18, 21 Of the four seasons that occur in the United States, the cold winter has the highest mortality and morbidity from myocardial infarction. 19, 22, 23 Cold temperatures increase the severity of cardiovascular disease and triggers myocardial infarction. [20] [21] [22] [23] [24] [25] [26] CH is an identified risk factor for myocardial infarction. Thus, appropriate control of CICH might decrease the high mortality rates from cardiovascular diseases in cold regions or in winter. Therefore, it is important to understand fully the mechanism mediating CICH. Cold exposure induces hypertension and CH in rats within 1-3 weeks. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] However, prevention or attenuation of cold-induced hypertension (CIH) does not attenuate CICH, indicating that CICH is not caused by high blood pressure (BP). [30] [31] [32] 37, 40, 42 Indeed, CIH is moderate hypertension (systolic BPE150 mm Hg). Thus, the development of CICH is independent of pressure overload, making it a unique animal model of CH to study. The present study employed CICH model also because it is a natural form of experimentally induced CH that does not require surgery (aortic banding), genetic manipulation, or large doses of drugs or hormones. To determine the role of increased c-Myc expression in CICH, we achieved selective inhibition of c-Myc in the heart using c-myc antisense driven by a heart-specific promoter, a-myosin heavy chain (MHC). To achieve c-myc antisense delivery, we used nonviral negatively charged nanospheres that have recently been shown to be effective for in vivo gene delivery in muscle. 43 We hypothesized that heart-specific inhibition of c-Myc expression attenuates CICH.
Results
Effects of c-MycAS on c-Myc protein expression in Rat heart (H9c2) cells c-MycAS significantly inhibited c-Myc protein expression in H9c2 cardiomyocytes (Figure 1b) . c-Myc protein expression was decreased by approximately 65.68% in cardiomyocytes transfected with c-pa-MHC-AntiMyc (c-MycAS) compared with cardiomyocytes transfected with pa-MHC-green fluorescent protein (GFP) or nontransfected cardiomyocytes. pa-MHC-GFP (GFP) did not affect c-Myc expression in cardiomyocytes (Figure 1b) . Strong GFP expression was found in cardiomyocytes while GFP was not detectable in non-myocardial Calu-6 cells after transfection with pa-MHC-GFP, indicating heart specificity of a-MHC (Figure 1c) .
Effects of cold exposure on BP, heat weight and c-Myc protein expression BP of the cold-exposed rats began to elevate at day 9 after exposure to cold and reached a level of 15276 mm Hg at day 35, while BP of rats maintained at room temperature remained unchanged (data not shown). In contrast, heart weight was increased significantly as early as day 7 after exposure to cold (Figure 2a) . Thus, the cold-induced increase in heart weight occurred before the coldinduced elevation of BP. Cold exposure increased cardiac c-Myc protein expression significantly at days 7, 21 and 35 after exposure to cold (Figure 2b ). c-Myc protein expression in the heart was approximately doubled in the cold-exposed rats compared with the room temperature-maintained rats. There was a significant correlation between the cold-induced increases in c-Myc protein expression and in heart weight (r ¼ 0.89, Po0.01).
Effects of c-MycAS on BP, body weight and cardiac output
BP of the GFP-and buffer-treated groups increased significantly at day 8 after exposure to cold (Figure 3a) . BP of these two groups reached a maximal level (E146 mm Hg) at day 21 and remained elevated thereafter. In contrast, BP of the c-MycAS-treated group did not increase until day 28 after exposure to cold, indicating that c-MycAS attenuated the development of CIH. BP of this group reached the level of GFP-Cold or the Buffer-Cold groups at day 42. Body weights of the four groups did not differ between each other ( Figure  3b ), indicating that c-mycAS or cold exposure did not affect the body weight gain.
Cardiac output was increased significantly in the GFPCold and the Buffer-Cold groups, indicating that cold exposure increased cardiac output (Figure 3c ). c-MycAS prevented the cold-induced increase in cardiac output at day 18 after gene delivery. Cardiac output of the c-MycAS-Cold group increased to the level of the GFP-Cold and the Buffer-Cold groups at day 42 (figure not shown).
Effects of c-MycAS on CICH
The magnetic resonance imaging (MRI) analysis indicated the in vivo left ventricle wall thickness was increased significantly at the end of both systole and diastole in the GFP-Cold and the Buffer-Cold groups at c-myc antisense on cold-induced cardiac hypertrophy M Bello Roufai et al day 18 after gene delivery (Figure 4a ). c-MycAS significantly attenuated the cold-induced increase in heart wall thickness. Cold exposure increased heart weights significantly (Figures 4b and c) . c-MycAS prevented the cold-induced increase in heart weights at day 18 after gene delivery (Figure 4b ), indicating that c-MycAS abolished CICH. Heart weight of c-MycASCold group increased to that of the GFP-Cold or the Buffer-Cold groups at day 42, indicating that the effect of c-MycAS on CH disappeared (Figure 4c ).
Histological examination of CH
In consistence with the heart weight changes, the enlarged heart was seen in cold-exposed rats treated with buffer or GFP (Figure 5a ). No obvious fibrosis was found in the heart in any groups of rats. The size of cardiomyocytes was increased in cold-exposed rats treated with buffer or GFP (Figure 5b ). The cardiomyocyte cross-sectional area (CSA) was increased significantly in the GFP-Cold and Buffer-Cold groups compared with the Buffer-Warm group (Figure 5c ), indicating that cold exposure caused cardiomyocyte hypertrophy. C-MycAS decreased the size of cardiomyocytes in the cold-exposed group to that of the BufferWarm group, indicating that heart-specific inhibition of c-Myc prevented cold-induced cardiomyocyte hypertrophy. c-Myc expression was measured in kidneys, liver, aorta, mesenteric arteries and brain to evaluate tissuespecific effect of c-MycAS. No significant difference in c-Myc expression was found in these tissues between any two of the cold-exposed groups at either day 18 or 42 (data not shown). These results indicated that c-MycAS did not affect c-Myc expression in tissues other than hearts, indicating cardiac specificity of a-MHC.
Effects of c-MycAS

Confirmation of cardiac specificity of a-MHC
GFP mRNA strongly expressed in the heart at day 18 after gene delivery ( Figure 7a ). GFP mRNA expression was not detectable in kidneys, liver, aorta, mesenteric arteries and brain, confirming cardiac specificity of a-MHC. Strong GFP expression was found in the cardiomyocytes ( Figure 7b ). GFP was localized in the nuclei and cytoplasma of cardiomyocytes ( Figure 7c ). GFP mRNA and GFP was not detectable at day 42 after gene delivery (data not shown).
Discussion
Our previous studies established that chronic cold exposure causes CH. [27] [28] [29] [30] [31] [32] However, the mechanism mediating CICH is unknown. The present data demonstrate that CICH was correlated with the cold-induced increase in cardiac c-Myc expression. To determine further if the increased c-Myc expression is involved in the pathogenesis of CICH, we suppressed cardiac c-Myc expression from the beginning of exposure to cold by using c-myc antisense driven by a heart-specific promoter. Interestingly, inhibition of cardiac c-Myc expression abolished the cold-induced increase in heart wall thickness, heart weight and cardiomyocyte size. To our knowledge, this is the first study showing that heartspecific antisense inhibition of c-Myc expression prevented the development of CH although the association of CH and increased c-myc expression was reported previously. 7, [12] [13] [14] [15] [16] A single dose of c-MycAS can suppress c-Myc expression and control CICH for at least 18 days. This study suggests, for the first time, that the increased c-Myc expression may mediate CICH. Previous studies from our laboratory indicate that CICH is independent of pressure overload because prevention or attenuation of CIH does not attenuate CICH. [30] [31] [32] 37, 40, 42 The present finding that the occurrence of CICH preceded that of CIH further reveals the disassociation of CICH and CIH. c-myc antisense on cold-induced cardiac hypertrophy M Bello Roufai et al
Cell culture studies showed that overexpression of c-myc in cardiac myocytes increased protein synthesis and increased myocyte size, indicating that increased expression of c-myc can induce cardiomyocyte hypertrophy. 7, 10 The most recent study by Zhong et al. 44 convincingly demonstrated that inducible inactivation of c-Myc in myocardium attenuated stress-induced CH in mice. They further showed that the attenuation of CH is attributed to a reduction in myocyte growth. 44 Indeed, CICH was mainly characterized by the increased myocyte size and no obvious fibrosis was found in the hypertrophied heart of cold-exposed rats. Because cardiomyocytes are terminally differentiated cells, cellular hypertrophy is their unique response to hypertrophic stimuli. Antisense inhibition of cardiac c-Myc expression prevented the cold-induced increase in cardiomyocyte size, suggesting that cold-induced cardiomyocyte hypertrophy was mediated by the increased cardiac c-Myc expression associated with cold exposure.
Although further studies are required to determine the mechanism of the cold-induced increase in cardiac c-Myc expression, the present data support the notion that Figure 3 Effects of rat c-myc antisense on cold-induced elevation of BP (a) and body weight (b) (mean7s.e.m.). Intravenous injections of c-myc antisense (c-MycAS) or GFP-driven by a heart-specific promoter were carried out immediately before exposure to cold. c-MycAS-Cold are rats treated with c-MycAS and exposed to cold; GFP-Cold are rats treated with GFP and exposed to cold. Buffer-Cold are rats treated with buffer and exposed to cold. Buffer-Warm are rats treated with buffer and kept at room temperature. Cardiac output (c) of the four groups measured at day 18 after injection. *Po0.05, **Po0.001 vs the GFP-Cold group; ++ Po0.001 vs the Buffer-Cold group (n ¼ 5). BP, blood pressure; GFP, green fluorescent protein.
c-myc antisense on cold-induced cardiac hypertrophy M Bello Roufai et al c-myc may serve as a potential target for controlling CICH. Numerous studies have shown that the sympathetic nervous system (SNS) or the rennin-angiotensin system (RAS) is not involved in CICH as evidenced by the fact that blockade of a-or b-adrenergic receptors or inhibition of the RAS at different levels does not attenuate CICH. 30, 32, 37, 40, 42, 45 It was found that circulating levels of thyroid hormones (T 3 and T 4 ) were increased by cold exposure and may be involved in CICH. 46 A cell culture study indicated that thyroid hormone-induced myocyte hypertrophy requires p38 mitogen-activated protein kinase (p38MAPK). 47 p38MAPK activates transcription factors such as c-myc. 48 Therefore, a new study is required to test the hypothesis that the cold-induced increase in c-Myc expression is mediated by the thyroid hormone-p38MAPK pathway. 
for the pathogenesis of CH. [3] [4] [5] [6] [7] [8] [9] Thus, the present finding raises the necessity to test the anti-hypertrophic effect of heart-specific inhibition of c-Myc on other forms of CH associated with increased c-Myc expression.
Unexpectedly, the inhibition of cardiac c-Myc expression also delayed and attenuated cold-induced elevation of BP. The antihypertensive effect of c-MycAS on CIH was not anticipated because the direct implication of cardiac c-Myc in BP regulation has never been reported. The antihypertensive effect of c-MycAS was likely due to the decreased cardiac output since c-MycAS did not affect c-Myc expression in arteries and kidneys. Although further studies are required to determine the mechanism, this finding indicates that inhibition of cardiac c-Myc expression suppressed the cardiac function enhanced by cold exposure as evidenced by the decreased stroke volume in the c-MycAS-Cold group. This result suggests, for the first time, that the increased cardiac output is essential to the development of CIH.
Heart specificity of a-MHC was confirmed by heartspecific inhibition of c-Myc in c-MycAS-treated rats and by heart-specific expression of GFP mRNA and protein in GFP-treated rats. The present study employed a nonviral nanostructure-based gene delivery system, which has been shown to be effective for in vivo local gene transfer. 43, 49 This negatively charged self-assembling DNA/poloxamine nanosphere can efficiently transfer reporter and therapeutic genes to skeletal and cardiac muscle via local injections. 43, 49, 50 The present study demonstrated that the systemic gene delivery via injection of this nanostructure-based complex into the circulation can effectively deliver c-MycAS and GFP to the heart. To our knowledge, this is the first report of using IV delivery of nanotechnique for cardiac gene transfer. This complex can carry the transgene into the cells as evidenced by strong GFP expression in the cytoplasma and nucleus of cardiomyocytes. The effect of c-MycAS and GFP expression lasted for at least 18 days. Figure 5 Histological examination of CH. Photomicrographs of hearts (a) and cardiomyocytes (b) and cell CSA (c) of a cold-exposed rat treated with c-MycAS, a cold-exposed rat treated with GFP, a cold-exposed rat treated with buffer, and a rat kept at room temperature (warm) and treated with buffer. The examination was carried out when animals were killed at day 18 after gene delivery.
+++
Po0.001 vs the BufferCold group. n ¼ 5. CH, cardiac hypertrophy; CSA, cross-sectional area; GFP, green fluorescent protein.
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The inhibitory effect of c-MycAS on BP diminished thereafter and disappeared at day 42 after gene delivery, suggesting that poloxamine-mediated gene transfer is not long lasting. This is apparently due to a decrease or loss of myocardial c-MycAS levels over this time. A longterm anti-hypertrophic effect may be achieved by repeated injections of the complex, thanks to the lack of immunogenicity associated with viral delivery. No obvious toxic effects were seen with this new gene delivery system as evidenced by normal growth rate of rats treated with the DNA/poloxamine complex.
In summary, heart-specific inhibition of c-Myc expression attenuated CIH and CICH. The antihypertensive effect of c-MycAS may be due to its suppressing effect on cardiac function (cardiac output) while the anti-hypertrophic effect of c-MycAS may be mediated by its inhibiting effect on the cardiomyocyte growth. The present finding suggests that the increased c-Myc expression plays a critical role in the pathogenesis of CICH. Heart-specific suppression of c-Myc may serve as a new and effective approach for the control of CH. Further studies are required to determine if c-MycAS affects the hypertrophic marker genes such as b-MHC and atria natriuretic factor (ANF).
Materials and methods
Construction of recombinant pa-MHC-GFP (GFP) and pa-MHC-antiMyc (c-MycAS) and preparation of plasmid delivery complex
The plasmid of mouse a-MHC (pa-MHC) clone 26 (Genebank, MMU71441) was used as a heart-specific promoter. pa-MHC-GFP (9.7 kb) was obtained by inserting the a-MHC promoter before GFP encoding pEGFP-1 (BD Clontech, Palo Alto, CA, USA). The sense and antisense sequence of c-myc was designed to target at gene sequence (nt 4166-nt 4499) of rat c-myc oncogene (accession no. Y00396). c-MycAS was constructed as illustrated in Figure 1a . pa-MHC-antiMyc was obtained by inserting a sequence encoding c-myc antisense DNA (334 bp) immediately after the a-MHC promoter ( Figure  1a ). Plasmids were extracted from recombinant Escherichia coli by using an endo-free plasmid purification kit (Qiagen Inc., Los Angeles, CA, USA).
The plasmid delivery system was made of plasmid DNA and nanostructure-based poloxamine 304 complexes (BASF Co.). Briefly, 5% stock solution of poloxamine 304 was made in sterilized water. To prepare the complexes, equal volumes of poloxamine 304 (5%) and the plasmid solution in 2 Â formulating buffer were mixed immediately before use in vivo for gene delivery. Formulating buffer (pH 7.4) contains 145 mM NaCl, 6 mM KCl, 3 mM Ca and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
Cells and in vitro transfection
Rat heart cells (H9c2) and non-myocardial Calu-6 cells (lung tumor cells) were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (ATCC, Manassas, CA, USA), 100 IU/ml penicillin and 100 mg/ml streptomycin. They were kept in an incubator with a humidified atmosphere (5% CO 2 and 95% air) at 371C. The transfection condition for each well was 70% cell confluence (1 ml), 8 mg of plasmid and 8 mg of CLONfectin complex (2 mg/ml, Invitrogen, Carlsbad, CA, USA). Cells were incubated in the presence of the complexes and were harvested to measure c-Myc and GFP expression after 72 h of incubation. Cell lysate was prepared for determination of c-Myc protein expression c-myc antisense on cold-induced cardiac hypertrophy M Bello Roufai et al using western blot as described in our previous studies. 32, 33 Briefly, the membranes were incubated with c-Myc mouse monoclonal antibody (NeoMarkers, Kelso, WA, USA) and b-actin mouse monoclonal antibody (Abcam, San Francisco, CA, USA). The membranes were then incubated with goat anti-mouse horseradish peroxidase (HRP)-labeled IgG antibody (BD Transduction Laboratories, Franklin Lakes, NJ, USA).
The transfected cells were passed (1:5) into the selective medium containing antibiotic G-418 sulfate solution (Promega, Madison, WI, USA). The GFP expression was detected by confocal fluorescence microscopy when the positive clones were obtained 10-14 days post-transfection.
Animals
This study was carried out according to the Guidelines of the National Institute of Health on the care and use of laboratory animals. The project, of which this study was a part, was approved by the Institutional Animal Care And Use Committee (IACUC). Male Sprague-Dawley rats (180-194 g) were used. All rats were housed individually in wire-mesh cages and were provided with Purina laboratory chow (no. 5001) and tap water ad libitum throughout the experiment.
Effects of cold exposure on BP, heart weight and cardiac c-Myc expression
To study the effect of cold exposure on cardiac c-Myc expression, four groups of rats were used (six rats per group). Three groups were moved to a cold chamber (6.7721C) while the last group was kept at an identical chamber maintained at room temperature (25721C, warm) and served as a control as described in our previous studies. 32, 33, 45 Relative humidity was controlled automatically at 4575% in both thermal environments. All rats were handled frequently (two times daily) to minimize handling stress. BP and body weight were measured daily. Resting systolic BP was measured using the tail-cuff method as detailed previously. [30] [31] [32] [33] 39 The three cold-exposed groups were killed at 7, 21 and 35 days after exposure to cold, respectively. The room temperature-maintained group was killed and served as a control. The heart was removed, weighed (mg/100 g body weight), and further processed for western blot analysis of cardiac c-Myc protein expression. A correlation analysis was carried out to determine the relationship between c-Myc protein expression and heart weight.
Effects of c-MycAS on CIH and CICH
To test the effect of c-MycAS on CICH, four groups of rats (10 rats/group) were used. BP and body weight were measured three times during a control period at room temperature (warm, 251C). All animals were handled frequently (two times a day) and trained to get used to the BP measurement procedure to minimize handling stress. Animals did not appear stressed during BP measurement. Resting systolic BP was measured at room temperature from the tail of each unanesthetized rat using the tail-cuff method with slight warming (281C) but not heating of the tail. The tail-cuff procedure is a common method used by us [30] [31] [32] [33] 39 and others 34, 35 to delineate CIH. It has been confirmed by the intraarterial cannulation that the noninvasive tail-cuff method is effective and reliable in monitoring systolic BP in rats exposed to cold. 27, 28 During the control period, five rats from each group were anesthetized (sodium pentobarbital, 75 mg/kg, intraperitoneally) and processed for in vivo cardiac MRI analysis to determine the left ventricular (LV) wall thickness and cardiac output.
After the control period, the four groups of animals received a bolus injection of c-MycAS/poloxamine 304 complex (c-MycAS, 0.8 mmol in 0.75 ml), GFP/poloxamine 304 complex (GFP, 0.8 mmol in 0.75 ml), formulating buffer (buffer, 0.75 ml) and formulating buffer (buffer, 0.75 ml), respectively, via the right jugular vein under anesthesia with sodium pentobarbital. Sense or scrambled AS was not used as a control construct c-myc antisense on cold-induced cardiac hypertrophy M Bello Roufai et al because it is known that it does not induce any phenotypic changes. 34 Following recovery, the c-MycAS group, the GFP group and one buffer group were exposed to cold (6.7721C) while the other buffer group was kept at room temperature (25721C, warm) and served as a control. BP and body weight were measured every 5 days during exposure to cold. At days 18 and 42 of cold exposure, five rats from each group were anesthetized and processed for cardiac MRI. The animals were then euthanasized and perfused through the heart with heparinized saline to remove blood from tissues. Hearts were removed, photographed and weighed (mg/ 100 g body weight). The heart/body weight ratio was expressed as fold changes compared with the BufferWarm rats. Heart, aorta, mesenteric arteries, liver and brain were snap-frozen in liquid nitrogen for later analysis of c-Myc and GFP expressions. A small part of each tissue was used for histological examination and localization of GFP.
Histological examination and Immunofluorescent analysis of GFP After perfusion, tissues were then collected and embedded with optimal cutting temperature compound (OCT compound). Tissues were cut at 5-8 mm and tissue sections were post-fixed with neutral-buffered formalin (10% neutral-buffered formalin (NBF)) for 30 min and incubated for 10 min with 0.25% Triton X-100. Some sections were used for histological examination using hematoxylin and eosin staining. Sections were examined and photographed using a Zeiss Axioplan II photomicroscope (Carl Zeiss) coupled with a highly sensitive Spot digital color camera. To assess the cardiomyocyte CSA, only round to ovoid cells were considered and at least 100 cells were counted in several images from the left ventricle. Cardiomyocyte areas were measured using the Spot software Version 3591.
Some tissue sections were used for immunofluorescent analysis of GFP. Tissue sections were incubated with Auto Fluorescence Blocker (Image iT Fx Enhancer; Invitrogen) for 30 min followed with protein blocker (Background sniper; Invitrogen) for 15 min. Sections were then incubated with Alexa-Fluor 488-labeled Anti-GFP antibody (Molecular Probes, Eugene, OR, USA) overnight at 41C. Following these procedures, sections were washed and mounted with Vectashield with DAPI. GFP was viewed using a confocal system (Nikon, Melville, NY, USA).
In vivo cardiac imaging
The in vivo cardiac imaging was accessed by MRI on a 4.7-T. Oxford Magnet using a Bruker Avance console and a ParaVision (Bruker BioSpin MRI Inc., Billerica, MA, USA) MRI system equipped with Master gradients and a five-element cardiac phased array receiver coil. A small animal Instrument monitoring and gating system for respiration rate and electrocardiogram (ECG)-synchronized triggering was adapted to the system. Dorsal and sagittal images were acquired using a cardiac gated gradient echo (GEFI_TOMO) sequence. On the basis of these views, transverse images were prescribed and were collected with the GEFI_TOMO sequence. The following parameters were used: FOV ¼ 4.0 Â 3.0 cm, matrix ¼ 256 Â 128; repetition time ¼ 0.158 ms; recovering time ¼ 13.22 ms; echo time ¼ 2.0 ms; pulse angle ¼ 301. Slice thickness was 2.0 mm. The image analysis was performed offline using the NIH Image J software version 1.33n (NIH, Bethesda, MD, USA). The left ventricle wall thickness was measured at end-diastole and end-systole on a series of three slices showing the maximum size of the two papillary muscles while they were still connected with the myocardium. The cardiac output was determined by the average stroke volume obtained from all slices and the average heart rate obtained from the immediate post-imaging period (cardiac output ¼ stroke volume Â heart rate). In all data sets, one experienced observer manually traced the endocardial and the epicardial contours of the left ventricle. The global myocardium thickness was determined by the difference between the epicardial and endocardial areas.
RT-PCR analysis of GFP mRNA expression
Total RNA was isolated using the trizol RNA isolation kit (Invitrogen). First-strand DNA was synthesized with SuperScript II reverse transcriptase (Invitrogen) by using 5 mg aliquot of the total RNA in 20 ml reaction mixture. Two microliters of cDNA were then used for PCR. Total RNA without reverse transcriptase were amplified and used as negative control to rule out the possible plasmid contamination. The template for the positive control was the pa-MHC-GFP. The GFP primers were 5 0 -CAGTGCTT CAGCCGCTACCC-3 0 (forward) and 5 0 -AGTTCACCTT GATGCCGTTCTT-3 0 (reverse). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were 5 0 -CCCTTCATTGACCTCAACTACATGG-3 0 (forward) and 5 0 -GAGGGGCCATCCACAGTCTTCTG-3 0 (reverse).
Western blotting
The western blot procedure was described previously. 32, 33 The primary antibody for c-Myc was a mouse monoclonal anti-cMyc (Lab Vision Corp., Fremont, CA, USA). The primary antibody for GAPDH was a mouse monoclonal anti-GAPDH (Labvision, Fremont, CA, USA). The secondary antibody was a goat anti-mouse-HRP-labeled antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). GAPDH protein expression was used as internal control to normalize cMyc expression within each sample. Enhanced chemiluminescence (ECL) was added to membranes and exposed to photosensitive films. Protein band intensities were quantified by using Quantity One version 4.1.1.1 software (BioRad, Hercules, CA, USA).
Statistical analysis
The data for BP and body weight were analyzed by a repeated measures one-way analysis of variance (ANOVA). The remaining data were analyzed by a oneway ANOVA. The Newman-Keuls procedure was used to access the significance of differences between means. Significance was set at the 95% confidence interval.
Abbreviations
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